NCT04364620 - AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 23, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions

NSCLC Stage IV

Interventions

DRUG

AB-16B5

AB-16B5 is an inhibitor of the epithelial to mesenchymal transition. It is a fully humanized monoclonal antibody of IgG2 isotype against tumor-associated secreted clusterin (TA-sCLU).

DRUG

Docetaxel

Docetaxel is an anticancer chemotherapy drug approved in the treatment of non-small cell lung cancer

Trial Locations (5)

77030

The University of Texas MD Anderson Cancer Center, Houston

H1T 2M4

Hôpital Maisonneuve-Rosemont, Montreal

H2X 3E4

Centre Hospitalier de l'Université de Montréal (CHUM), Montreal

G1V 4G5

Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ), Québec

J7Z 5T3

Centre Intégré de Santé et de Services Sociaux des Laurentides (Hôpital Régional de St-Jérôme), Saint-Jérôme